Blog

qordata thought leaders and subject matter experts share their insights and experiences

Mohammad Ovais
Written By
Mohammad Ovais
February 21, 2018
0 Comments

Even the best efforts at pharmaceutical compliance will fail unless the power of analytics is fully harnessed. As qordata prepares companies for their CMS spend submission this year, it continues to discover some astounding outliers in reports medical drug and device companies submitted to the CMS in previous years. These data oversights will earn up to $1.15 million in penalties from the CMS per company. The consistency with which these records have been entered since 2014 can only suggest three things. Pharmaceutical companies either: • Don’t know the seriousness of the issue, • Don’t have enough time for a spend review or • Need help with their spend reporting process CMPs Not Serious Enough? When it comes to Big Pharma […]

Kristin Buske
Written By
Kristin Buske
February 5, 2018
0 Comments

Data crunching, monitoring, risk management—traditionally, we have never seen these activities form part of what is the glamorous realm of the brand manager’s toolkit. But—as regulators strive to bring transparency and distributive justice to the pharmaceutical industry, best compliance practices may actually be inching their way into active branding. Perception Reality Gap: “Marketing is the war of perceptions,” is a familiar truism in business textbooks. It’s something marketing professionals have always known, frequently exploited, and increasingly—fallen victim to, themselves too. As access to data gets easier and quicker, the risk of falling victim to one’s own (mis)-perceptions is magnified manifold. ‘Gut instincts’ are only 50% accurate, and going by them, or a superficial, irregular presentation of sales figures gives brand […]

Ned Mumtaz
Written By
Ned Mumtaz
February 5, 2018
0 Comments

February might prove to be a definitive month for CMS, as it proposes changes to its Medicare Health and Drug Programs, effective 2019. The changes are predicted to make Medicare Advantage more flexible, providing beneficiaries with more options and benefits. Motivating these changes is CMS’ goal of fighting the opioid crisis by revitalizing the doctor-patient communication/relationship. What’s Set To Change Senior citizens will be able to enjoy a wider range of options, and lowered payments for premiums as part of their Medicare Health/Drug Plans.  The CMS has widened the definition of supplemental benefits to include assistive devices, portable wheelchair ramps, non-skilled in-home supports and others, a departure from its previous definition of supplemental benefit, which limited items to non-daily maintenance. […]

Mohammad Ovais
Written By
Mohammad Ovais
January 30, 2018
0 Comments

We now continue the dialogue on the many benefits proactive physician profiling offers pharmaceutical companies. In today’s post, we describe them from the perspective of physicians and the drug manufacturing companies. For Your Physicians: Could your sales teams be missing diamonds-in-the-rough? It’s possible, especially if your competition hasn’t caught on yet, or is just beginning to. Proactive pre-submission analytics help you make decisions relevant to your competitive environment. You can, for example: Discover your physicians’ spend relationship relative to your competitors, by way of spend category (R&D versus General Payments), length and depth of the spend relationship, activity and quality of engagement. Sales performance as a function of spend activity Medicare Part D fraud, if any, or potential for the […]

Upcoming Event

6th Annual Compliance Monitoring

27 Feb to 28 Feb, 2018
9:00 am To 6:00 pm EST
DETAILS

Ask an Expert

Get all the insights, and the answers to the most critical issues in pharma compliance from thought leaders in qorcommunity

Get Answer

OUR SOLUTIONS CAN SIMPLIFY YOUR COMPLIANCE EFFORTS.